Onglyza

The dosage of Saxagliptin must be individualized based on the patient's current treatment regimen, effectiveness, and tolerability. According to standard clinical guidelines:

• Standard Adult Dose: The recommended dose for most adults is 2.5 mg or 5 mg taken orally once daily.
• Maximum Dose: The maximum recommended dose is 5 mg once daily. Increasing the dose beyond 5 mg does not typically result in significantly better blood sugar control but may increase the risk of side effects.
• Combination with CYP3A4/5 Inhibitors: If you are taking strong inhibitors of the CYP3A4/5 enzyme (such as ketoconazole, clarithromycin, or ritonavir), the dose of Saxagliptin should be limited to 2.5 mg once daily.

The safety and effectiveness of Saxagliptin in pediatric patients (under the age of 18) have not been established. As of 2024, clinical trials are ongoing to determine its profile in children, but it is currently not FDA-approved for pediatric use. Healthcare providers generally prefer other established treatments for type 2 diabetes in children.

Renal Impairment

Because Saxagliptin and its active metabolite are partially cleared by the kidneys, dosage adjustments are necessary for patients with decreased kidney function:

• Mild Renal Impairment (CrCl > 50 mL/min): No dosage adjustment is required.
• Moderate to Severe Renal Impairment (CrCl ≤ 50 mL/min): The dose should be limited to 2.5 mg once daily. This includes patients with End-Stage Renal Disease (ESRD) requiring hemodialysis. For patients on dialysis, Saxagliptin should be administered after the hemodialysis session.

Hepatic Impairment

No dosage adjustment is recommended for patients with mild, moderate, or severe hepatic (liver) impairment. However, clinicians should use caution in patients with severe liver disease due to limited clinical data in this specific population.

Elderly Patients

No specific dosage adjustment is required based solely on age. However, because elderly patients are more likely to have decreased renal function, kidney function (creatinine clearance) should be assessed before and during treatment to determine if the 2.5 mg dose is appropriate.

To get the most benefit from Saxagliptin, follow these instructions carefully:

• Consistency: Take your dose at the same time each day to maintain steady levels in your bloodstream.
• Food: Saxagliptin can be taken with or without food. If it causes an upset stomach, taking it with a meal may help.
• Administration: Swallow the tablet whole. Do not crush, chew, or split the tablets, as this can affect how the medication is absorbed (especially in extended-release combination versions).
• Storage: Store the medication at room temperature (68°F to 77°F or 20°C to 25°C), away from moisture, heat, and direct light.

If you miss a dose of Saxagliptin, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects.

In the event of an overdose, contact your local poison control center or seek emergency medical attention immediately. While Saxagliptin has a relatively wide safety margin, an overdose may lead to excessive DPP-4 inhibition and potential gastrointestinal distress. Symptoms of a significant overdose may not be immediately apparent, but medical monitoring of blood glucose and supportive care are standard protocols.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to dangerous spikes in blood sugar levels.

Most patients tolerate Saxagliptin well, but some may experience mild to moderate side effects. Common side effects reported in clinical trials include:

• Upper Respiratory Tract Infection: This may feel like a common cold, characterized by a runny nose, sore throat, or nasal congestion. These symptoms typically resolve on their own.
• Urinary Tract Infection (UTI): Patients may experience a frequent urge to urinate or a burning sensation during urination. It is important to report these symptoms to a doctor to ensure appropriate antibiotic treatment if needed.
• Headache: Mild to moderate headaches are common when starting the medication but often diminish as the body adjusts to the drug.

• Gastrointestinal Issues: Some patients report nausea, vomiting, or stomach discomfort. These are often transient and improve over time.
• Peripheral Edema: Swelling of the hands, ankles, or feet. This is more common when Saxagliptin is used in combination with a thiazolidinedione (like pioglitazone).
• Hypoglycemia: While Saxagliptin itself rarely causes low blood sugar, the risk increases significantly if it is used with insulin or a sulfonylurea (like glipizide).

• Severe Joint Pain (Arthralgia): In 2015, the FDA issued a warning that DPP-4 inhibitors like Saxagliptin may cause severe and disabling joint pain. This can occur anywhere from one day to years after starting the drug. Symptoms usually resolve after stopping the medication.
• Bullous Pemphigoid: This is a rare autoimmune skin condition that causes large, fluid-filled blisters. If you notice skin blistering or erosions, seek medical help immediately.
• Hypersensitivity Reactions: These include serious allergic reactions such as anaphylaxis, angioedema (swelling of the face, lips, or tongue), and exfoliative skin conditions.

> Warning: Stop taking Saxagliptin and call your doctor immediately if you experience any of the following serious conditions:

1. 1Pancreatitis (Inflammation of the Pancreas): This is a life-threatening condition. Symptoms include severe, persistent abdominal pain that may radiate to your back, with or without vomiting.
2. 2Heart Failure: Data from the SAVOR-TIMI 53 clinical trial suggested an increased risk of hospitalization for heart failure in patients taking Saxagliptin, particularly those with pre-existing heart or kidney disease. Symptoms include shortness of breath (especially when lying down), unusual tiredness, or rapid weight gain with swelling.
3. 3Severe Allergic Reaction: Signs include hives, difficulty breathing, or swelling of your face, lips, tongue, or throat.

With prolonged use, the primary concerns involve the continued monitoring of renal function and heart health. There is currently no evidence that Saxagliptin causes long-term damage to the pancreas in the absence of acute pancreatitis episodes, but long-term registry studies continue to monitor for any delayed adverse effects. Some patients may experience a gradual decrease in the drug's efficacy over many years as the underlying diabetes progresses, which is a common feature of many oral diabetes medications.

No FDA black box warnings currently exist for Saxagliptin. However, the FDA does require prominent warnings in the 'Warnings and Precautions' section of the label regarding the risk of heart failure and acute pancreatitis.

Report any unusual symptoms or persistent side effects to your healthcare provider. Monitoring your body's response is a critical part of managing diabetes effectively.

Saxagliptin is a powerful tool for managing blood sugar, but it requires careful monitoring. Patients must be aware that Saxagliptin is not a substitute for insulin in patients who require insulin for survival. It should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Before starting therapy, ensure your provider has a full list of your medical conditions, particularly any history of pancreatitis, gallstones, alcoholism, or high triglycerides, as these increase the risk of pancreatic complications.

As of 2024, there are no FDA black box warnings for Saxagliptin. However, the absence of a black box warning does not mean the drug is without risk. The warnings for heart failure and pancreatitis are considered significant clinical concerns.

• Heart Failure Risk: In a large cardiovascular outcomes trial (SAVOR-TIMI 53), more patients receiving Saxagliptin (3.5%) were hospitalized for heart failure compared to those receiving a placebo (2.8%). Patients with a history of heart failure or renal impairment should be monitored closely for signs and symptoms of heart failure during therapy.
• Pancreatitis: There have been post-marketing reports of acute pancreatitis in patients taking Saxagliptin. If pancreatitis is suspected, the drug should be discontinued immediately and not restarted.
• Renal Function: Because Saxagliptin is renally excreted, kidney function should be evaluated prior to initiation and periodically thereafter. Dose reduction is mandatory for patients with moderate to severe renal impairment.
• Severe Arthralgia: Patients should be informed that severe and disabling joint pain may occur. If this happens, the medication should be discontinued under medical supervision.
• Bullous Pemphigoid: If a patient develops blisters or skin erosions while taking a DPP-4 inhibitor, the drug should be stopped, and a referral to a dermatologist should be considered.

To ensure Saxagliptin is working safely and effectively, your healthcare provider will likely order the following tests:

• HbA1c (Hemoglobin A1c): Checked every 3 to 6 months to monitor long-term blood sugar control.
• Renal Function Tests (Serum Creatinine/eGFR): Checked at baseline and at least annually to ensure the dosage remains appropriate for your kidney function.
• Blood Glucose Monitoring: Regular home testing to identify patterns of high or low blood sugar.

Saxagliptin itself does not typically cause drowsiness or impaired coordination. However, if used in combination with other diabetes drugs that cause hypoglycemia (like insulin), the resulting low blood sugar can impair your ability to drive or operate heavy machinery. Always ensure your blood sugar is stable before performing these tasks.

Alcohol can affect blood sugar levels in unpredictable ways. Excessive alcohol consumption while taking Saxagliptin can increase the risk of pancreatitis and may also increase the risk of hypoglycemia. It is generally recommended to limit alcohol intake and discuss your habits with your doctor.

Do not stop taking Saxagliptin abruptly unless you experience a serious side effect like pancreatitis or a severe allergic reaction. Stopping the medication suddenly can cause your blood sugar to rise rapidly (rebound hyperglycemia). If you need to stop the medication, your doctor will provide a plan to transition you to another therapy.

> Important: Discuss all your medical conditions, especially heart or kidney problems, with your healthcare provider before starting Saxagliptin.

There are no absolute 'never use' contraindications involving specific drug-drug interactions that apply to all patients, but the use of Saxagliptin with strong CYP3A4/5 inhibitors without a dose reduction is clinically contraindicated. Combining these drugs without adjusting the Saxagliptin dose to 2.5 mg can lead to dangerously high levels of the medication in the blood, increasing the risk of toxicity.

• Strong CYP3A4/5 Inhibitors: Drugs such as ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, and atazanavir significantly increase the concentration of Saxagliptin. The dose of Saxagliptin must be limited to 2.5 mg once daily when used with these agents.
• Insulin and Sulfonylureas: When Saxagliptin is added to insulin or a sulfonylurea (e.g., glyburide, glimepiride), the risk of hypoglycemia (dangerously low blood sugar) is increased. Your doctor may need to lower the dose of your insulin or sulfonylurea to prevent this.

• Corticosteroids (e.g., Prednisone): These medications can raise blood sugar levels, effectively counteracting the benefits of Saxagliptin. Close monitoring of blood glucose is required.
• Thiazide Diuretics: Medications like hydrochlorothiazide can increase blood sugar, potentially requiring an adjustment in diabetes therapy.
• Beta-Blockers: These drugs may mask the symptoms of low blood sugar (such as a fast heartbeat), making it harder for you to recognize when your sugar is dropping.

• Grapefruit Juice: Grapefruit is a known inhibitor of the CYP3A4 enzyme. While not as potent as some medications, consuming large amounts of grapefruit juice may increase Saxagliptin levels. It is best to consume grapefruit in moderation or avoid it.
• High-Fat Meals: As noted in the pharmacokinetics section, food does not significantly affect the absorption of Saxagliptin, so it can be taken regardless of meal timing.

• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4. It may speed up the metabolism of Saxagliptin, potentially reducing its effectiveness and leading to higher blood sugar levels.
• Fenugreek and Ginseng: These supplements may have blood-sugar-lowering effects of their own. Taking them with Saxagliptin could theoretically increase the risk of hypoglycemia.
• Aloe Vera (Oral): May also lower blood glucose and should be used with caution.

Saxagliptin does not typically interfere with standard laboratory tests. However, it will affect your HbA1c and blood glucose readings, which is the intended therapeutic effect. Always inform your lab technician of all medications you are taking.

For each major interaction, the mechanism involves the CYP3A4/5 enzymatic pathway. Inhibitors slow down the breakdown (increasing toxicity risk), while inducers speed it up (reducing efficacy). Management strategies usually involve dose adjustment or increased frequency of blood glucose monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as many interactions can be managed with proper dose adjustments.

Absolute contraindications are conditions under which Saxagliptin should never be used because the risks far outweigh any potential benefits. These include:

• Hypersensitivity: Any patient with a known history of a serious hypersensitivity reaction (e.g., anaphylaxis, angioedema, or exfoliative skin conditions) to Saxagliptin or any other DPP-4 inhibitor (such as sitagliptin or linagliptin) must not take this medication. The mechanism is an immune-mediated allergic response that can be life-threatening.
• Type 1 Diabetes: Saxagliptin is ineffective in type 1 diabetes because it relies on the presence of some endogenous insulin production, which is absent in type 1 patients.
• Diabetic Ketoacidosis (DKA): This is an emergency condition requiring rapid-acting insulin and intravenous fluids; Saxagliptin has no role in its management.

Relative contraindications require a careful risk-benefit analysis by a healthcare professional:

• History of Pancreatitis: Because Saxagliptin has been associated with acute pancreatitis, patients with a history of this condition should be treated with extreme caution, as they may be at higher risk for recurrence.
• Heart Failure: Patients with pre-existing heart failure or those at high risk (e.g., those with kidney disease) should be evaluated carefully, given the data suggesting an increased risk of hospitalization for heart failure.
• Moderate to Severe Renal Impairment: While not a total contraindication, these conditions require mandatory dose reduction to 2.5 mg to avoid drug accumulation.

Patients who have had an allergic reaction to other 'gliptins' (DPP-4 inhibitors) should be aware of the potential for cross-sensitivity. While the chemical structures differ slightly, the pharmacological class is the same, and similar hypersensitivity reactions have been reported across the class. If you have ever had swelling of the face or throat after taking a diabetes pill, inform your doctor immediately.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies, before prescribing Saxagliptin to ensure it is safe for you.

Saxagliptin is classified under the former FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. According to the American Diabetes Association (ADA), insulin is typically the preferred agent for managing diabetes during pregnancy. Saxagliptin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not currently recommended for use in fertility treatments.

It is not known whether Saxagliptin is excreted in human milk. However, animal studies have shown that Saxagliptin is secreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Most clinicians recommend alternative treatments with better-established safety profiles for breastfeeding mothers.

As of 2024, Saxagliptin is not approved for use in patients under the age of 18. The safety and efficacy have not been established in this population. Clinical trials in pediatric populations are complex, and until more data is available, pediatric type 2 diabetes is usually managed with metformin, insulin, or GLP-1 receptor agonists that have specific pediatric indications.

In clinical trials, no overall differences in safety or effectiveness were observed between patients 65 years and older and younger patients. However, greater sensitivity in some older individuals cannot be ruled out. The primary concern in the elderly is the natural decline in kidney function (renal clearance). Because the dose of Saxagliptin must be adjusted based on renal function, it is vital to monitor the eGFR of elderly patients regularly. There is no significantly increased fall risk directly associated with Saxagliptin, but polypharmacy (taking multiple medications) in the elderly increases the risk of drug interactions.

Renal impairment significantly affects the levels of Saxagliptin and its active metabolite in the body.

• Mild (CrCl > 50 mL/min): No dose adjustment.
• Moderate to Severe (CrCl ≤ 50 mL/min): Dose must be reduced to 2.5 mg once daily.
• Hemodialysis: Saxagliptin is removed by hemodialysis. Therefore, it should be administered following the dialysis session on dialysis days. Careful monitoring of blood sugar is required as kidney function fluctuates.

Clinical data suggest that no dosage adjustment is needed for patients with any degree of hepatic impairment (Child-Pugh Class A, B, or C). The pharmacokinetics of Saxagliptin are not significantly altered by liver disease, although the overall health and metabolic state of patients with severe liver disease should be considered by the prescribing physician.

> Important: Special populations require individualized medical assessment and frequent monitoring to ensure the safety of diabetes therapy.

Saxagliptin is a highly potent and selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the rapid degradation of the incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are released by the intestines throughout the day, and levels increase in response to a meal. By inhibiting DPP-4, Saxagliptin extends the half-life of active GLP-1 and GIP. This stabilization leads to increased insulin synthesis and release from pancreatic beta cells and decreased glucagon secretion from pancreatic alpha cells. Importantly, these effects are glucose-dependent, meaning they occur primarily when blood glucose concentrations are elevated, thereby reducing the risk of hypoglycemia.

Following a single oral dose of 5 mg, DPP-4 enzyme activity is inhibited by more than 80% for at least 24 hours. This prolonged inhibition is due to the high affinity of Saxagliptin for the enzyme and the contribution of its active metabolite, 5-hydroxy saxagliptin. The onset of action is rapid, with significant reductions in postprandial glucose seen after the first dose. Tolerance does not typically develop, and the glucose-lowering effect remains consistent with long-term daily use.

| Parameter | Value |

|---|---|

| Bioavailability | ~67% |

| Protein Binding | Negligible (0-10%) |

| Half-life (Parent) | 2.5 hours |

| Half-life (DPP-4 Inhibition) | ~27 hours |

| Tmax (Peak Time) | 2 hours (Parent), 4 hours (Metabolite) |

| Metabolism | Hepatic via CYP3A4/5 to active metabolite |

| Excretion | Renal 60% (24% as parent), Fecal 22% |

The molecular formula of Saxagliptin hydrochloride is C18H25N3O2 • HCl. It has a molecular weight of 351.87 g/mol. Chemically, it is a cyclopropylglycine-based compound. It is a white to light yellow or brown powder that is soluble in water and sparingly soluble in ethanol. Its structure allows it to form a reversible covalent bond with the active site of the DPP-4 enzyme, which explains its high potency and selectivity.

Saxagliptin is classified as a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor. It belongs to the broader category of incretin-based therapies. Other medications in this same class include sitagliptin (Januvia), linagliptin (Tradjenta), and alogliptin (Nesina). These drugs are distinct from SGLT2 inhibitors (which act on the kidneys) and GLP-1 receptor agonists (which are typically injectable and mimic the hormone directly).